GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Debt-to-Equity

Gyre Therapeutics (Gyre Therapeutics) Debt-to-Equity : -0.03 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Debt-to-Equity?

Gyre Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.2 Mil. Gyre Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.2 Mil. Gyre Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-15.8 Mil. Gyre Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was -0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Gyre Therapeutics's Debt-to-Equity or its related term are showing as below:

GYRE' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.03   Med: 0.01   Max: 0.02
Current: -0.03

During the past 3 years, the highest Debt-to-Equity Ratio of Gyre Therapeutics was 0.02. The lowest was -0.03. And the median was 0.01.

GYRE's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs GYRE: -0.03

Gyre Therapeutics Debt-to-Equity Historical Data

The historical data trend for Gyre Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Debt-to-Equity Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-Equity
0.02 0.01 -0.03

Gyre Therapeutics Semi-Annual Data
Dec21 Dec22 Dec23
Debt-to-Equity 0.02 0.01 -0.03

Competitive Comparison of Gyre Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Gyre Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gyre Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's Debt-to-Equity falls into.


Gyre Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Gyre Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.21 + 0.199) / -15.828
=-0.03

Gyre Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.21 + 0.199) / -15.828
=-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gyre Therapeutics  (NAS:GYRE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Gyre Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics (Gyre Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Debt-to-Equity
Comparable Companies
Traded in Other Exchanges
L9S:Germany
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Website
https://www.gyretx.com
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines

From GuruFocus

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

By PRNewswire • 12-15-2023